Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 Clinical efficacy  





3 History  





4 Society and culture  



4.1  Economics  







5 Research  





6 References  














Romiplostim






العربية
Deutsch
فارسی
Français
Italiano
עברית
Lietuvių

ି
Română
Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Türkçe
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Romiplostim
Clinical data
Trade namesNplate, others
Other namesAMG531
AHFS/Drugs.comMonograph
MedlinePlusa609008
License data
Pregnancy
category
  • AU: B3
  • Routes of
    administration
    Subcutaneous
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only[1]
  • Pharmacokinetic data
    Elimination half-life1 to 34 days
    Identifiers
    • L-methionyl[human immunoglobulin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7′:10,10′)-bisdisulfide dimer

    CAS Number
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    ChEMBL
    Chemical and physical data
    FormulaC2634H4086N722O790S18
    Molar mass59085.01 g·mol−1
     ☒NcheckY (what is this?)  (verify)

    Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.

    The most common side effects in adults include headache, infections of the nose and throat, and allergic (hypersensitivity) reactions such as rash, itching and rapid swelling under the skin.[1] The most common side effects in children include infections of the nose and throat, runny nose, cough, fever, mouth and throat pain, abdominal (belly) pain, diarrhea, rash, and bruising.[1]

    Medical uses[edit]

    Romiplostim is indicated as a potential treatment for chronic idiopathic (immune) thrombocytopenic purpura (ITP).[2]

    Clinical efficacy[edit]

    In well designed, 24-week, Phase III trials, romiplostim was significantly more effective than placebo in achieving the primary endpoint of a protocol-defined durable platelet response in nonsplenectomized or splenectomized adults with chronic immune thrombocytopenic purpura.[3]

    History[edit]

    Romiplostim was developed by Amgen through a restricted usage program called NEXUS.[4] During development and clinical trials the drug was called AMG531.[5]

    Romiplostim was designated an orphan drug by the US Food and Drug Administration (FDA) in 2003[6]

    In August 2008, the FDA approved romiplostim as a long-term treatment for chronic immune thrombocytopenia in adults who have not responded to other treatments, such as corticosteroids, intravenous immunoglobulin, Rho(D) immune globulinorsplenectomy.[4][7]

    Society and culture[edit]

    Economics[edit]

    The wholesale cost of romiplostim if administered weekly is currently estimated at US$55,250 per year.[8]

    Research[edit]

    Romiplostim may be used to treat acute radiation syndrome.[9] "To reduce radiation-induced bleeding, Nplate stimulates the body’s production of platelets. The drug can be used to treat adults and children."[9]

    References[edit]

    1. ^ a b c "Nplate EPAR". European Medicines Agency (EMA). 27 May 2005. Retrieved 16 May 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  • ^ Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. (February 2008). "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial". Lancet. 371 (9610): 395–403. doi:10.1016/S0140-6736(08)60203-2. PMID 18242413. S2CID 23827197.
  • ^ Frampton JE, Lyseng-Williamson KA (2009). "Romiplostim". Drugs. 69 (3): 307–317. doi:10.2165/00003495-200969030-00006. PMID 19275274.
  • ^ a b Waknine Y (4 September 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. Retrieved 4 September 2008.
  • ^ Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. (October 2006). "AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP". The New England Journal of Medicine. 355 (16): 1672–1681. doi:10.1056/NEJMoa054626. PMID 17050891.
  • ^ "Amgen to Discuss Romiplostim BLA". drugs.com. 12 March 2008. Retrieved 4 November 2008.
  • ^ "FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP" (Press release). Amgen. 22 August 2008. Archived from the original on 15 September 2008. Retrieved 4 September 2008.
  • ^ Perreault S, Burzynski J (May 2009). "Romiplostim: a novel thrombopoiesis-stimulating agent". American Journal of Health-System Pharmacy. 66 (9): 817–824. doi:10.2146/ajhp080524. PMID 19386944.
  • ^ a b Roberts L (5 October 2022). "US splashes $290m on anti-radiation drugs after Putin ups nuclear threats". The Daily Telegraph. Retrieved 10 October 2022.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Romiplostim&oldid=1229044237"

    Categories: 
    Antihemorrhagics
    Orphan drugs
    Thrombopoietin receptor agonists
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from May 2024
    Drugs with non-standard legal status
    Articles with changed CASNo identifier
    Chemicals that do not have a ChemSpider ID assigned
    Articles with changed EBI identifier
    Articles without InChI source
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
     



    This page was last edited on 14 June 2024, at 14:56 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki